MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com

Investment analysts at StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP) in a report released on Tuesday. The firm set a “buy” rating on the stock.

Separately, Stifel Nicolaus restated a “hold” rating and issued a $7.00 price objective on shares of MEI Pharma in a research report on Friday, April 12th.

MEI Pharma Trading Down 2.1 %

MEIP opened at $2.85 on Tuesday. The company has a market cap of $18.98 million, a P/E ratio of 0.73 and a beta of 0.86. MEI Pharma has a 1-year low of $2.73 and a 1-year high of $7.87. The company has a fifty day moving average price of $2.99 and a two-hundred day moving average price of $4.02.

MEI Pharma (NASDAQ:MEIP) last announced its earnings results on Thursday, May 9th. The company reported ($1.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.01. On average, research analysts forecast that MEI Pharma will post 3.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MEI Pharma stock. National Bank of Canada FI purchased a new stake in shares of MEI Pharma, Inc. (NASDAQ:MEIP) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned approximately 0.09% of MEI Pharma at the end of the most recent reporting period. 52.38% of the stock is currently owned by institutional investors.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.